252 related articles for article (PubMed ID: 24137801)
21. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.
Gynther M; Ropponen J; Laine K; Leppänen J; Haapakoski P; Peura L; Järvinen T; Rautio J
J Med Chem; 2009 May; 52(10):3348-53. PubMed ID: 19402664
[TBL] [Abstract][Full Text] [Related]
22. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
Kärkkäinen J; Gynther M; Kokkola T; Petsalo A; Auriola S; Lahtela-Kakkonen M; Laine K; Rautio J; Huttunen KM
Int J Pharm; 2018 Jun; 544(1):91-99. PubMed ID: 29669256
[TBL] [Abstract][Full Text] [Related]
23. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
Huttunen J; Gynther M; Vellonen KS; Huttunen KM
Int J Pharm; 2019 Nov; 571():118714. PubMed ID: 31610281
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of
Lee KE; Kang YS
J Biomed Sci; 2017 May; 24(1):28. PubMed ID: 28490336
[TBL] [Abstract][Full Text] [Related]
25. Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line.
Takahashi Y; Nishimura T; Higuchi K; Noguchi S; Tega Y; Kurosawa T; Deguchi Y; Tomi M
Pharm Res; 2018 Oct; 35(12):246. PubMed ID: 30374619
[TBL] [Abstract][Full Text] [Related]
26. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.
Uchino H; Kanai Y; Kim DK; Wempe MF; Chairoungdua A; Morimoto E; Anders MW; Endou H
Mol Pharmacol; 2002 Apr; 61(4):729-37. PubMed ID: 11901210
[TBL] [Abstract][Full Text] [Related]
27. Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs.
Gynther M; Pickering DS; Spicer JA; Denny WA; Huttunen KM
Mol Pharm; 2016 Jul; 13(7):2484-91. PubMed ID: 27266990
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and characterization of 9-[P-(N, N-dipropyl sulfamide)] benzoylamino-1,2,3,4-4H-acridine--a potential prodrug for the CNS delivery of tacrine.
Gong T; Huang Y; Zhang ZR; Li LL
J Drug Target; 2004 Apr; 12(3):177-82. PubMed ID: 15203897
[TBL] [Abstract][Full Text] [Related]
29. Altering distribution profile of palbociclib by its prodrugs.
Järvinen J; Montaser AB; Adla SK; Leppänen J; Lehtonen M; Vellonen KS; Laitinen T; Jalkanen A; Elmquist WF; Timonen J; Huttunen KM; Rautio J
Eur J Pharm Sci; 2024 Jan; 192():106637. PubMed ID: 37967656
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis and Enhanced BBB Penetration Studies of L-serine-Tethered Nipecotic Acid-Prodrug.
Dhanawat M; Gupta S; Mehta DK; Das R
Drug Res (Stuttg); 2021 Feb; 71(2):94-103. PubMed ID: 33241549
[TBL] [Abstract][Full Text] [Related]
31. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
Bhunia S; Vangala V; Bhattacharya D; Ravuri HG; Kuncha M; Chakravarty S; Sistla R; Chaudhuri A
Mol Pharm; 2017 Nov; 14(11):3834-3847. PubMed ID: 28958145
[TBL] [Abstract][Full Text] [Related]
32. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells.
Patel M; Dalvi P; Gokulgandhi M; Kesh S; Kohli T; Pal D; Mitra AK
Int J Pharm; 2013 Feb; 443(1-2):245-53. PubMed ID: 23270998
[TBL] [Abstract][Full Text] [Related]
33. L-Type amino acid transporter 1 as a target for drug delivery.
Puris E; Gynther M; Auriola S; Huttunen KM
Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
[TBL] [Abstract][Full Text] [Related]
35. LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?
Rautio J; Gynther M; Laine K
Ther Deliv; 2013 Mar; 4(3):281-4. PubMed ID: 23442072
[No Abstract] [Full Text] [Related]
36. Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234.
Boado RJ; Li JY; Pardridge WM
J Neurochem; 2003 Mar; 84(6):1322-31. PubMed ID: 12614332
[TBL] [Abstract][Full Text] [Related]
37. L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors.
Huttunen KM; Huttunen J; Aufderhaar I; Gynther M; Denny WA; Spicer JA
Int J Pharm; 2016 Feb; 498(1-2):205-16. PubMed ID: 26705152
[TBL] [Abstract][Full Text] [Related]
38. Aminopeptidase B can bioconvert L-type amino acid transporter 1 (LAT1)-utilizing amide prodrugs in the brain.
Hugele A; Löffler S; Molina BH; Guillon M; Montaser AB; Auriola S; Huttunen KM
Front Pharmacol; 2022; 13():1034964. PubMed ID: 36339537
[TBL] [Abstract][Full Text] [Related]
39. Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival.
Tampio J; Huttunen J; Montaser A; Huttunen KM
Mol Neurobiol; 2020 Nov; 57(11):4563-4577. PubMed ID: 32754897
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and in vitro studies on a potential dopamine prodrug.
Giannola LI; De Caro V; Giandalia G; Siragusa MG; Lamartina L
Pharmazie; 2008 Oct; 63(10):704-10. PubMed ID: 18972830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
